Stay updated on ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial
Sign up to get notified when there's something new on the ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial page.

Latest updates to the ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check22 days agoChange DetectedThe page has been updated to include new information about the clinical trial for ARV-471 in breast cancer, including a new revision number and the removal of extensive details about the trial's design and inclusion/exclusion criteria.SummaryDifference19%
- Check29 days agoChange DetectedThe web page has updated its version from v2.14.3 to v2.14.4, and a date has been added for February 11, 2025. However, the deletion of the date March 25, 2025, does not significantly impact the core content.SummaryDifference0.3%
- Check37 days agoChange DetectedThe page has been updated to reflect a new version release, moving from v2.14.2 to v2.14.3, and the last update date has changed from February 11, 2025, to March 25, 2025.SummaryDifference0.2%
- Check73 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1%
- Check80 days agoChange DetectedThe webpage has updated the clinical trial information for ARV-471, including new dates and the removal of previous trial details, indicating a shift in the timeline and status of the trial.SummaryDifference1%
Stay in the know with updates to ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the ARV-471 & Palbociclib in ER+/HER2- mBC Clinical Trial page.